MONROVIA, CA, March 19, 2009
/24-7PressRelease/ -- Dr. Joseph Bolen, Chief Scientific Officer of Millennium Pharmaceuticals, Inc. will be the keynote speaker at GTCbio's 4th Annual Protein Kinases in Drug Discovery Conference taking place on May 4-5, 2009 in Boston, Massachusetts.
Dr. Bolen will deliver his keynote address entitled "Preclinical Imperatives for Translational Continuity in the Clinical Development of Protein Kinase Inhibitors" at this year's conference. The presentation will highlight the importance of aligning disease and treatment hypotheses with kinase drug action in the context of early clinical trials. Dr. Bolen will discuss what the minimum quantitative and qualitative correlations are to provide a knowledge base sufficient to enhance the accuracy of critical decision making during the translational phase of drug assessment.
Dr. Bolen joined Millennium in 1999 as Vice President of Oncology and was promoted to Senior Vice President of Discovery Research in 2002. In this role, he headed all biological research in the areas of oncology, inflammation, metabolic disease and cardiovascular disease as well as all genomics, informatics and platform technologies. In 2003 Dr. Bolen was appointed Senior Vice President of Research and Drug Discovery, a role in which he headed all biological research and related functions as well as all drug discovery functions. Dr. Bolen was appointed Chief Scientific Officer in 2006.
The 4th Annual Protein Kinases in Drug Discovery Conference taking place on May 4-5, 2009 in Boston, Massachusetts will cover topics such as Drug Design Trends, Overcoming Challenges of Kinase Drug Development, Case Studies on Taking Pre-Clinical Kinase Targets to Clinical trials, and Novel Kinases and Inhibitor Candidates.
For more information including a detailed agenda, exhibitor opportunities and registration information visit http://gtcbio.com/conferenceDetails.aspx?id=149
About GTCbio
GTCbio organizes conferences specifically for the biomedical and biopharmaceutical industries. Our goal is to facilitate the exchange of biopharmaceutical and biomedical intelligence between industry leaders, academic and government organizations, and the financial community.
GTCbio is a subsidiary of Global Technology Community, LLC, a privately held company founded in 2002.
---
Press release service and press release distribution provided by http://www.24-7pressrelease.com# # #
Read more Press Releases from Rania Hafez:- Joost Oppenheim, M.D., Laboratory Chief - NCI, to give Keynote Presentation at GTCbio's 8th Cytokines & Inflammation Conference on January 28-29, 2010 in San Diego, CA
- Vaccines: All Things Considered Conference to be held by GTCbio on November 9-10, 2009 in Washington, DC
- Translational Medicine Track of the GTCbio 5th Annual Modern Drug Discovery & Development Conference to be held on October 14-16, 2009 in San Diego, CA
- Amy Scott-Billman, VP at GlaxoSmithKline to do Keynote at Modern Drug Discovery & Development Summit
- Biological Therapeutics to be an Important Focus at the 5th Modern Drug Discovery & Development Summit held by GTCbio on October 14-16, 2009 in San Diego, CA.
- GTCbio Announces 4th Annual Assay Development and Screening Conference taking place June 8-9, 2009.
- GTCbio Announces its Inaugural Ocular Diseases & Drug Discovery conference, taking place on April 20-21, 2009 in Philadelphia, Pennsylvania.
- Pete Adamson, Head of Research for Ophthiris at GlaxoSmithKline to give Keynote Presentation at GTCbio's Inaugural Ocular Diseases & Drug Discovery conference, taking place on April 20-21, 2009 in Philadelphia, PA.
- Alison Goss Eng of US Dept. of Energy to Present at GTCbio's Inaugural Biofuels: Science and Innovation for Sustainable Development Conference on June 29-30, 2009 in San Francisco, CA
- GTCbio Announces its Inaugural Ocular Diseases & Drug Discovery conference, taking place on April 20-21, 2009 in Philadelphia, Pennsylvania.
